JP Morgan Call 180 CHKP 19.07.202.../ DE000JB9BED2 /
| 2024-06-06 10:38:10 AM | Chg.+0.003 | Bid12:36:25 PM | Ask12:36:25 PM | Underlying | Strike price | Expiration date | Option type |
|---|---|---|---|---|---|---|---|
| 0.009EUR | +50.00% | 0.009 Bid Size: 1,000 |
0.110 Ask Size: 1,000 |
Check Point Software... | 180.00 USD | 2024-07-19 | Call |
GlobeNewswire
4:00 AM
CHECKPOINT ALERT: Bragar Eagel & Squire, P.C. is Investigating Checkpoint Therapeutics, Inc. on Beha...
GlobeNewswire
06-05
Ocean Biomedical (NASDAQ: OCEA) Congratulates Joint Venture Partner, Virion Therapeutics, on Positiv...
GlobeNewswire
06-05
OSE Immunotherapeutics and Nantes University Hospital Present Positive Phase 1/2 Study Evaluating FR...
GlobeNewswire
06-04
DEADLINE TODAY: The Schall Law Firm Encourages Investors in Checkpoint Therapeutics, Inc. with Losse...
GlobeNewswire
06-04
Indaptus Therapeutics to Present New Positive Data on Decoy20 at Next-Gen Immuno-Oncology Conference
GlobeNewswire
06-04
CKPT DEADLINE TOMORROW: ROSEN, A LEADING LAW FIRM, Encourages Checkpoint Therapeutics, Inc. Investor...
GlobeNewswire
06-03
Ascendis Pharma Presents New Data and Updated Results from Phase 1/2 IL-Believe Trial at ASCO 2024
GlobeNewswire
06-03
7 Hills Pharma Receives $4.7MM Grant to Advance First-in-class Cell/Gene Therapy Technology into the...
GlobeNewswire
06-03
DEADLINE ALERT for CKPT, OCGN, SOND, QDEL: Law Offices of Howard G. Smith Reminds Investors of Class...
GlobeNewswire
06-03
INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Ch...
GlobeNewswire
06-03
DEADLINE ALERT for HRT and CKPT: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions...
GlobeNewswire
06-03
CKPT INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Checkpoint Therapeutics, Inc. ...
GlobeNewswire
06-03
ORYZON Announces Journal Publication of Final Phase IIa ALICE Results with Iadademstat in The Lancet...
GlobeNewswire
06-02
ALX Oncology Presents First Evorpacept Combination Data with an Antibody-Drug Conjugate from Phase 1...
GlobeNewswire
06-02
Nanobiotix Announces New Data Showing Disease Control and Tumor Response in Patients Treated With RT...
GlobeNewswire
06-01
Affimed Provides Follow-up Data of AFM24 plus Atezolizumab Showing Durable Responses in Heavily Pret...
GlobeNewswire
06-01
Investigational Acasunlimab (DuoBody® -PD-L1x4-1BB) in Combination with Pembrolizumab Demonstrates M...
GlobeNewswire
06-01
Werewolf Therapeutics to Present Data from Ongoing Phase 1/1b Clinical Trial of WTX-124 as Monothera...
GlobeNewswire
06-01
Purple Biotech Announces Positive Late-Breaking Interim Randomized Phase 2 Data at ASCO 2024 Demonst...
GlobeNewswire
06-01
CHECKPOINT DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit...
